Indivior is a pharmaceutical company specialising in addiction treatment. Indivior was spun out of parent Reckitt Benckiser in December 2014. Adding to its Suboxone opioid addiction product, the company has a pipeline including longer-lasting 'depot' formulations, treatments for cocaine intoxication, alcohol addiction and even schizophrenia, as a psychiatric co-morbidity of addiction.
| CEO: |
Mark Crossley |
| Chairman: |
Graham Hetherington |
| Non-Executive Director: |
Jerome Lande |
| Senior Independent Director: |
Juliet Thompson |
| Independent Non-Executive Director: |
Mark Stejbach, David E. Wheadon, Barbara Ryan, Peter Bains, Jo Le Couilliard, Keith Humphreys |
| CFO & Executive Director: |
Ryan Preblick |
| Address: |
234 Bath Road, Slough, Berkshire, United Kingdom |
| Phone: |
|
| Fax: |
|
| Website: |
http://www.Indivior.com |
| Email: |
|